Results 191 to 200 of about 26,368 (251)

Real-world comparative effectiveness of FOLFIRINOX versus gemcitabine/nab-paclitaxel in metastatic pancreatic cancer: prognostic impact of metastatic site and burden in a Middle Eastern cohort. [PDF]

J Gastrointest Oncol
Eldehna WM, Elbarbry F, Shakra RA, Elrasad SA, Morsi ZA, Soaida SM, Wagdy WM, Aljohani AI, Abbas RM.   +8 more
europepmc   +1 more source

Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study. [PDF]

EClinicalMedicine
Wang F, Hao X, Geng C, Lin Y, Liu Z, Fu P, Liu Q, Yu Z, Jiang Z.   +8 more
europepmc   +1 more source

Efficacy and safety of the S-1, nab-paclitaxel, and gemcitabine triplet regimen in patients with resected pancreatic ductal adenocarcinoma. [PDF]

Front Oncol
Ran D, Geng C, Cha Z, Nie X, Atigu A, Zhao C, Xu X.   +6 more
europepmc   +1 more source

Pneumocystis Pneumonia in a Patient Receiving Nab-paclitaxel Plus Gemcitabine for Unresectable Pancreatic Cancer. [PDF]

Intern Med
Takano A, Himeji D, Shiiba R, Kushima N, Kinoshita E, Kamiike R, Tanaka GI, Arita S.   +7 more
europepmc   +1 more source

Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan. [PDF]

EClinicalMedicine
Hirata K, Hamamoto Y, Shoji H, Hara H, Kondoh C, Yasui H, Kajiwara T, Baba E, Ando T, Sugimoto N, Kawakami H, Katsuya H, Nagase M, Yamamoto Y, Yoshimura K, Ando M, Imamura CK, Yamazaki K, Hironaka S, Muro K.   +19 more
europepmc   +1 more source

Prognostic impact of thyroid transcription factor-1 expression and the efficacy of carboplatin plus (nab-) paclitaxel in non-squamous non-small cell lung cancer complicated with idiopathic interstitial pneumonias. [PDF]

Transl Lung Cancer Res
Terashima Y, Fukuizumi A, Kamio K, Abe I, Miyake E, Miyadera K, Kato Y, Hisakane K, Nakamichi S, Takeuchi S, Miyanaga A, Terasaki Y, Kasahara K, Seike M.   +13 more
europepmc   +1 more source

A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer. [PDF]

Cell Rep Med
Shi S, Zhang J, Liu R, Gao S, Xu J, Wang W, Wei M, Li J, Liu C, Xu X, Pan W, Tian X, Men L, Wang H, Liang Z, Zhu M, Yang D, Zhai Y, Yu X.   +18 more
europepmc   +1 more source

Prognostic Impact of Unplanned Hospitalization During First-Line Gemcitabine Plus Nab-Paclitaxel Therapy for Unresectable Pancreatic Cancer: A Single-Center Retrospective Observational Study. [PDF]

Cancers (Basel)
Watabe K, Kan M, Ohno I, Uchida S, Sudo T, Yokozuka K, Abe A, Nakaya Y, Ogane Y, Kurosaki H, Sakai M, Sekine Y, Takahashi T, Ouchi M, Ohyama H, Sakai N, Takano S, Takayashiki T, Ohtsuka M, Kato J.   +19 more
europepmc   +1 more source

The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer - the SERAPHINA study. [PDF]

J Cancer Res Clin Oncol
Schneeweiss A, Fasching PA, Thill M, van Mackelenbergh M, Marme F, Tesch H, Fehm TN, Park-Simon TW, Häberle L, Uhrig S, Tome O, Spall T, Theuser AK, Ruebner M, Belleville E, Wallwiener D, Brucker SY, Hartkopf AD.   +17 more
europepmc   +1 more source

Celecoxib pretreatment and nab-paclitaxel-associated acute pain syndrome in patients with breast cancer: a prospective, non-randomized controlled clinical study. [PDF]

Int J Surg
Liang F, Lu G, Sun D, Chen P, Shi Y, Peng H, Zeng T, Hu M, Zhu K, Qiu K, Chen X.   +10 more
europepmc   +1 more source